To the best of our knowledge, this study demonstrates for the first time the use of an anti-EGFR probe 89Zr-matuzumab and an anti-EGFR therapeutic agent nimotuzumab-PEG6-DM1 for simultaneous epitope-specific imaging and therapy of a receptor overexpressed on cancer cells. This evidence concerns the gene EGFR and cancer.